For example, MLL rearrangements and the poor prognostic NPM1 + FLT3-ITD + DNMT3A + subset3 (~ 7% and ~ 12.5% in the Leucegene cohort, respectively) were frequently associated with low expression levels of HMGA2. Based on these findings, we propose a new algorithm integrating the HMGA2 test in current strategies for AML prognostic assessment (Supplementary Figure S10). The gene discussed is HMGA2; the disease is acute myeloid leukemia.